The U.S. FDA declined to approve Daiichi Sankyo Co.’s drug quizartinib as a treatment for adults with a type of blood cancer.
A Japanese government panel approved a price of 33.5 million yen ($305,800) for Novartis’ cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment.
EMD Serono and Pfizer announced that the U.S. FDA approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma.
The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.
Vivek Ramaswamy’s Roivant Sciences has launched another “vant” company, this time in China, in a partnership with Hong Kong-based Sinovant Sciences.
Astellas Pharma’s blood cancer drug Xospata continues to show impressive results in the acute myeloid leukemia setting.
Japanese scientists will test the use of human-induced pluripotent stem cells (iPS) to treat spinal cord injuries, a health ministry panel that approved the research project said.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The Japanese subsidiary of Pfizer Inc. is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in the active ingredient valsartan, the drugmaker said.
U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation aimed at lowering the cost of prescription drugs for U.S. consumers.